Archive
LATE MOVERS: Symantec shares surge on the back of strong earnings results
Mellanox Technologies, the Israeli-based computer group also saw shares rise continue to rise on Thursday
Company
Pfizer Inc
NYSE:PFE
Pfizer Inc is a research-based biopharmaceutical company. The company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1.
293 stories · page 9 of 15
CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial
Leronlimab shows promise as an antiviral agent with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
LATE MOVERS: Apple rallies after posting 1Q earnings that beat analysts' estimates
eBay advanced after hours as the online auction company beat estimates for quarterly sales thanks to a busy holiday period
GSK chairman steps down after consumer healthcare merger with Pfizer
GSK chairman Sir Philip Hampton said following a deal with Pfizer to merge their consumer businesses, he believes "this is the right moment" to step down
Investments and investor services
EARLY MOVERS: FedEx stock sinks as Trump's trade wars bite
Chipmaker says global glut in semiconductor supplies to hit earnings
GlaxoSmithKline spikes higher as it inks US$12.7bn consumer healthcare deal with Pfizer
GSK will own 68% of the combined entity, which brings together products such as Panadol and Advil
IPO Roundup: Non-opioid pain treatment developer Centrexion Therapeutics set to IPO
The Massachusetts-based biopharma is led by former Pfizer CEO Jeffrey B. Kindler
GlaxoSmithKline releases upbeat injectable HIV treatment results
Trials for ViiV Healthcare's once-a-month injection show it is as effective as the current standard of care for HIV patients
Pfizer narrows full year guidance as third quarter earnings beat forecasts but revenues disappoint
"We believe we are well-positioned to develop and commercialize differentiated new medicines, creating sustainable value for shareholders and patients," said Pfizer boss Ian Read.
EARLY MOVERS: Pfizer in focus pre-market as plans emerge to cut around 2% of global workforce; Endocyte leaps on Novartis deal
The billionaire owner of Golden Nugget Casinos Tilman Fertitta wants to do a deal with Caesars Entertainment Corp
Archive
EARLY MOVERS: General Electric has a power surge on CEO news; while Tesla puts pedal to metal too
Also in the frame in pre-market with more boardroom news was Pfizer Inc..
Investments and investor services
Exact Sciences stock surges on report of marketing collaboration with Pfizer
The two companies will co-promote the cancer screening test in fourth quarter of 2018
FTSE 100 closes higher as hopes grow for US, China trade talks
FTSE 100 closed ahead as the new trading week began, but off the 7,600 level, adding over 32 points to 7,591
Antares misses on earnings, but deal with Pfizer bolsters outlook
Market is focused on deal between Antares and Pfizer and ignoring a miss on earnings per share
Wall Street finishes July on a high note, led by Illumina, Pfizer
In Toronto, the TSX pushed about 86 points higher to close at 16,431.
Pfizer 2Q earnings beat Street on higher sales of Prevnar vaccine, arthritis drug Xeljanz
The New York drug giant boosted its full-year profit forecast, but trimmed its sales forecast warning that weakening currencies in Europe, Asia could nick revenue
Leap Therapeutics reveals new cancer drug trial collaboration with Merck KGaA and Pfizer
Phase 1/2 clinical trial to see whether TRX518, avelumab and chemotherapy shrinks advanced tumors in patients with relapsed or refractory ovarian, breast and prostate cancers
PRE-MARKET MOVERS: Fastenal fires up in pre-market after earnings top estimates, while Pfizer fizzes higher too
Also in play in pre-market is Morgan Stanley and its promotion and retailer Macy's..
PRE-MARKET MOVERS: Pfizer shares pick up in pre-market deals while PepsiCo peps up too
Also in the frame in pre-market was Lowe's Companies Inc and J M Smucker Co
Avacta Group appoints Immunocore’s Eliot Forster as non-executive chairman
The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director